Mráz M, Doubek M, Mayer J
Interní Hematologická a Onkologická Klinika LF MU a FN Brno.
Klin Onkol. 2013;26(3):179-85. doi: 10.14735/amko2013179.
Chronic lymphocytic leukemia (CLL) is the most frequent, yet by conventional therapy still incurable, leukemia in the Western world. Accumulating evidence of the role of B cell receptor (BCR) pathway in CLL B cell bio-logy suggests the possible use of BCR inhibitors for targeted therapy. Recently published results of clinical trials of three different molecules (fosfamatinib, ibrutinib and GS 1101) targeting BCRassociated kinases (Syk, Btk, PI3K) showed impressive clinical activity in CLL. These findings will likely modify treatment approaches for chronic lymphocytic leukemia and some other B cell lymphomas in the near future. Herein, we review the data on BCR pathway deregulation in malignant CLL B cells, and the results of clinical trials utilizing fosfamatinib, ibrutinib and GS 1101.
慢性淋巴细胞白血病（CLL）是西方世界最常见但仍无法通过传统疗法治愈的白血病。越来越多的证据表明B细胞受体（BCR）通路在CLL B细胞生物学中发挥作用，这提示了BCR抑制剂可能用于靶向治疗。最近发表的针对三种不同分子（福斯替尼、依鲁替尼和GS-1101）靶向BCR相关激酶（Syk、Btk、PI3K）的临床试验结果显示，其在CLL中具有令人瞩目的临床活性。这些发现可能会在不久的将来改变慢性淋巴细胞白血病以及其他一些B细胞淋巴瘤的治疗方法。在此，我们综述了恶性CLL B细胞中BCR通路失调的数据，以及使用福斯替尼、依鲁替尼和GS-1101的临床试验结果。
